Diffuse fine speckled (DFS70) antibody in ANA testing: identification and proposed management in a New Zealand tertiary hospital setting.

Objectives: DFS70 antibody gives an ANA Immunofluorescent (IIF) staining pattern (homogeneous/speckled), frequently at high titre that is often seen in AARD patients although DFS70 antibody is rarely associated with systemic autoimmune - based rheumatic disease. The purposes of this study were to (a...

Descripción completa

Detalles Bibliográficos
Publicado en:New Zealand Journal of Medical Laboratory Science Vol. 71; no. 3; pp. 113 - 120
Autores principales: Austin, Paul M., McCarthy, Sinead M., Faiva-Thompson, Helena T.
Formato: algorithm research tables/charts Journal Article
Publicado: New Zealand Institute of Medical Laboratory Science Nov2017
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=126249059&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 126249059
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        11710195
        H2G
      jtl: New Zealand Journal of Medical Laboratory Science
      issn: 11710195
      maglogo: N
    pubinfo:
      dt: Nov2017
      vid: 71
      iid: 3
      pid: 12822
      pub: New Zealand Institute of Medical Laboratory Science
    artinfo:
      ui:
        126249059
        126249059
        126249059
        126249059
      ppf: 113
      ppct: 7
      formats:
        fmt:
          @attributes:
            type: P
      tig:
        atl: Diffuse fine speckled (DFS70) antibody in ANA testing: identification and proposed management in a New Zealand tertiary hospital setting.
      aug:
        au:
          Austin, Paul M.
          McCarthy, Sinead M.
          Faiva-Thompson, Helena T.
        affil: LabPLUS, Auckland City Hospital
      sug:
        subj:
          Fluorescent Antibody Technique Methods
          Autoantibodies Immunology
          Autoantibodies Analysis
          Rheumatic Diseases Immunology
          Rheumatic Diseases Diagnosis
          New Zealand
          Immunoassay
          Chemiluminescent Measurements
          In Vitro Studies
          Data Analysis Software
          Child
          Adolescence
          Adult
          Middle Age
          Aged
          Aged, 80 and Over
          Female
          Male
          Human
          Child: 6-12 years
          Adolescent: 13-18 years
          Adult: 19-44 years
          Middle Aged: 45-64 years
          Aged: 65+ years
          Aged, 80 & over
          Female
          Male
      ab: Objectives: DFS70 antibody gives an ANA Immunofluorescent (IIF) staining pattern (homogeneous/speckled), frequently at high titre that is often seen in AARD patients although DFS70 antibody is rarely associated with systemic autoimmune - based rheumatic disease. The purposes of this study were to (a) identify if DFS70 antibody was present in our test population (b) determine if DFS70 patterns could be identified with first-round IIF ANA testing (c) establish the relationships between IIF, CMIA (Chemiluminescence) and LIA (Line Immunoassay) methodologies for identification of DFS70 antibody and (d) propose a testing algorithm for implementation at LabPLUS that would allow the identification of DFS70 antibody. This is the first published study on a NZ patient cohort Methods: Patients referred for routine ANA testing were selected as presumptive DFS70 antibody positive and were then subsequently tested by both CMIA (INOVA Diagnostics BIOFLASH™) and LIA (Euroimmun EUROLINE Profile 3 Plus DFS70™) methodologies. Results: DFS70 antibody was proven to occur in NZ patients referred for ANA testing. IIF methodology in the hands of experienced operators correctly identified approximately 80% of DFS70 antibody positive patients. As second round confirmatory assays, both the CMIA and LIA methodologies were effective in the role. Conclusions: On the basis of the results of the study a testing algorithm was designed to allow the identification and reporting of DFS70 antibody. It is believed that when testing is implemented there will be significant fiscal benefits from reduced inappropriate testing as well as improved rheumatology outpatient clinic patient triaging over time. We further believe that implementation of DFS70 antibody testing and reporting will, for a proportion of patients reduce their anxiety and greatly reduce if not completely eliminate the opportunity for inappropriate treatment based on apparently significant ANA results.
      pubtype: Academic Journal
      doctype:
        algorithm
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N